Amira Pharmaceuticals is a forward-thinking player in the Biotechnology and Pharmaceutical sectors, founded in 2005. The company is dedicated to the discovery and development of small molecule drugs targeting inflammatory diseases.
By leveraging its expertise in bioactive lipid pathways and signaling processes, Amira Pharmaceuticals aims to revolutionize treatments for conditions like asthma, chronic obstructive pulmonary disease, and fibrotic diseases. Its focus on early-stage innovation places it in a unique position to address unmet medical needs.
The company secured a significant $25.00M Series B investment on March 23, 2007. This round was backed by notable investors including Novo Holdings, Avalon Ventures, Prospect Venture Partners, and Versant Ventures. This funding underscores investor confidence in Amira Pharmaceuticals' strategic approach and potential for high-impact breakthroughs in inflammatory disease treatment.
